As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
The U.S. Food and Drug Administration approved Gilead Sciences’ Epclusa for hepatitis C (HCV) for use in children as young as 6 years of age or who weigh at least 17 kilograms.
An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
Spring Bank Pharmaceuticals, based in Hopkinton, Massachusetts, is discontinuing development of inarigivir soproxil for chronic hepatitis B virus (HBV).
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.
Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
A U.S. appeals court dealt a major blow to Merck & Co. Inc., upholding a ruling that threw out a $2.54 billion (£1.97 billion) jury verdict the drugmaker had won against Gilead Sciences Inc.
Gilead Sciences Inc. reported third-quarter results largely in line with Wall Street estimates, led by higher sales of the company’s HIV drugs, but deal-related costs led to a net loss.
The U.S. Food and Drug Administration identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co. Inc., Gilead Sciences Inc. and AbbVie Inc.
GlaxoSmithKline exercised an option to license Ionis Pharmaceuticals’ antisense medicines for people with chronic hepatitis B virus infection following positive Phase 2 results.